title: Treatment of peripubertal children after renal transplantation (RTX) with recombinant human growth hormone: auxological data and effects on insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) during 24 months.
abstract: OBJECTIVE
  To evaluate growth and endocrine parameters in RTX children with GH treatment during 24 months.
  
  
  METHODS
  18 children (13 boys), age 13.1 yr (8.0-16.6), bone age 10.1 yr (5.4-15.3). Patients were 2.8 yr (0.5-7.5) after RTX and had immunosuppressive therapy, prednisone 0.16 mg/kg/d (0.08-0.68).
  
  
  METHODS
  GH (4 IU/m2/day s.c.) was given and patients were seen every 3 months for evaluation of height, height velocity, bone age, and hormone parameters. Serum IGF-I was determined by RIA, IGFBP-3 by RIA and Western ligand blotting (WLB). Renal function and adverse effects (GFR, glucose tolerance, rejection episodes) were monitored.
  
  
  RESULTS
  Height (+1 SDS) and height velocity (+2.2 SDS) increased significantly during 24 months GH treatment, but delta BA/delta CA was 1.7 and 1.5 during the first and second treatment year, respectively, and all patients entered puberty during the treatment period. GFR decreased slightly during 2 yr (p = 0.048), two patients had chronic rejection and GH therapy was terminated in one patient because of glucose intolerance. The ratio IGF-I/IGFBP-3 rose during the first year (p = 0.002) indicating more bioavailable IGF-I. IGFBP-3 determined by WLB was decreased, but IGFBP-1, -2 and -4 were elevated as compared to a standard.
  
  
  CONCLUSIONS
  GH treatment increased height and growth rate in children after RTX. This may be due to significant changes in IGF-I and IGFBP-3 relationship. However, bone maturation was also accelerated thus diminishing height potential. From month 12 to 24 a continuous decrease of IGF-I was observed. There was a slight but significant deterioration of graft function. Adverse events that led to termination of GH therapy were observed in 3 of 18 patients.
authors.affiliation: Pediatric Department, University Hospital of Vienna, Austria.
authors.forename: S
authors.initials: S
authors.lastname: Riedl
authors.forename: J
authors.initials: J
authors.lastname: Lebl
authors.forename: M
authors.initials: M
authors.lastname: Kluge
authors.forename: J
authors.initials: J
authors.lastname: Kreisinger
authors.forename: E
authors.initials: E
authors.lastname: Simková
authors.forename: C
authors.initials: C
authors.lastname: Kohlhauser
authors.forename: E
authors.initials: E
authors.lastname: Balzar
authors.forename: H
authors.initials: H
authors.lastname: Frisch
mesh_terms: D000293:Adolescent; D015153:Blotting, Western; D001827:Body Height; D002648:Child; D005260:Female; D019382:Human Growth Hormone / Q000627:therapeutic use*; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D016030:Kidney Transplantation; D008297:Male; D011182:Postoperative Care; D011627:Puberty / Q000502:physiology*; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D018972:Insulin-Like Growth Factor Binding Protein 3; D018969:Insulin-Like Growth Factor Binding Proteins; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D007334:Insulin-Like Growth Factor I